184 related articles for article (PubMed ID: 10451483)
1. The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast.
Tan DS; Potts HW; Leong AC; Gillett CE; Skilton D; Harris WH; Liebmann RD; Hanby AM
J Pathol; 1999 Sep; 189(1):20-7. PubMed ID: 10451483
[TBL] [Abstract][Full Text] [Related]
2. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
3. Anomalous expression of P-cadherin in breast carcinoma. Correlation with E-cadherin expression and pathological features.
Palacios J; Benito N; Pizarro A; Suárez A; Espada J; Cano A; Gamallo C
Am J Pathol; 1995 Mar; 146(3):605-12. PubMed ID: 7534041
[TBL] [Abstract][Full Text] [Related]
4. Expression of E-cadherin (E-CD) as related to other prognostic factors and survival in breast cancer.
Lipponen P; Saarelainen E; Ji H; Aaltomaa S; Syrjänen K
J Pathol; 1994 Oct; 174(2):101-9. PubMed ID: 7965405
[TBL] [Abstract][Full Text] [Related]
5. Separating favorable from unfavorable prognostic markers in breast cancer: the role of E-cadherin.
Heimann R; Lan F; McBride R; Hellman S
Cancer Res; 2000 Jan; 60(2):298-304. PubMed ID: 10667580
[TBL] [Abstract][Full Text] [Related]
6. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
Moll R; Mitze M; Frixen UH; Birchmeier W
Am J Pathol; 1993 Dec; 143(6):1731-42. PubMed ID: 8256859
[TBL] [Abstract][Full Text] [Related]
7. The prognostic significance of P-cadherin in infiltrating ductal breast carcinoma.
Gamallo C; Moreno-Bueno G; Sarrió D; Calero F; Hardisson D; Palacios J
Mod Pathol; 2001 Jul; 14(7):650-4. PubMed ID: 11454996
[TBL] [Abstract][Full Text] [Related]
8. [Immunohistochemical study of P-cadherin in breast cancer].
Kovács A; Walker RA; Nagy A; Gomba S; Jones L; Dearing S
Orv Hetil; 2002 Feb; 143(8):405-9. PubMed ID: 11921707
[TBL] [Abstract][Full Text] [Related]
9. E-cadherin as a prognostic indicator in primary breast cancer.
Parker C; Rampaul RS; Pinder SE; Bell JA; Wencyk PM; Blamey RW; Nicholson RI; Robertson JF
Br J Cancer; 2001 Dec; 85(12):1958-63. PubMed ID: 11747340
[TBL] [Abstract][Full Text] [Related]
10. Automated quantitative analysis of E-cadherin expression in lymph node metastases is predictive of survival in invasive ductal breast cancer.
Harigopal M; Berger AJ; Camp RL; Rimm DL; Kluger HM
Clin Cancer Res; 2005 Jun; 11(11):4083-9. PubMed ID: 15930343
[TBL] [Abstract][Full Text] [Related]
11. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast.
Gillett CE; Miles DW; Ryder K; Skilton D; Liebman RD; Springall RJ; Barnes DM; Hanby AM
J Pathol; 2001 Apr; 193(4):433-41. PubMed ID: 11276001
[TBL] [Abstract][Full Text] [Related]
12. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
13. E-cadherin expression in invasive non-lobular carcinoma of the breast and its prognostic significance.
Rakha EA; Abd El Rehim D; Pinder SE; Lewis SA; Ellis IO
Histopathology; 2005 Jun; 46(6):685-93. PubMed ID: 15910600
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
15. High expression levels of p27 correlate with lymph node status in a subset of advanced invasive breast carcinomas: relation to E-cadherin alterations, proliferative activity, and ploidy of the tumors.
Kouvaraki M; Gorgoulis VG; Rassidakis GZ; Liodis P; Markopoulos C; Gogas J; Kittas C
Cancer; 2002 May; 94(9):2454-65. PubMed ID: 12015771
[TBL] [Abstract][Full Text] [Related]
16. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807
[TBL] [Abstract][Full Text] [Related]
17. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
18. Mitotic counts provide additional prognostic information in grade II mammary carcinoma.
Lynch J; Pattekar R; Barnes DM; Hanby AM; Camplejohn RS; Ryder K; Gillett CE
J Pathol; 2002 Mar; 196(3):275-9. PubMed ID: 11857489
[TBL] [Abstract][Full Text] [Related]
19. Significance of E-cadherin/beta-catenin complex and cyclin D1 in breast cancer.
Lim SC; Lee MS
Oncol Rep; 2002; 9(5):915-28. PubMed ID: 12168049
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer.
Voutilainen KA; Anttila MA; Sillanpää SM; Ropponen KM; Saarikoski SV; Juhola MT; Kosma VM
J Clin Pathol; 2006 May; 59(5):460-7. PubMed ID: 16461565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
